First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers

Table 2 Summary of reported adverse events by dose

	2-Hydroxybenzylamine acetate dose						Total (n = 18)
	50 mg (n = 3)	100 mg (n = 3)	200 mg (n = 3)	330 mg (n = 3)	550 mg (n = 3)	825 mg (n = 3)	Total (n = 18)
Any event, n (%)	3 (100)	0	1 (33)	1 (33)	0	0	5 (28)
Frequent urination	2 (67)	0	0	0	0	0	2 (11)
Headache	0	0	1 (33)	0	0	0	1 (5.5)
Itchy throat	1 (33)	0	0	0	0	0	1 (5.5)
Rash	1 (33)	0	0	0	0	0	1 (5.5)
Sleepiness	1 (33)	0	0	0	0	0	1 (5.5)
Abdominal bloating	0	0	0	1 (33)	0	0	1 (5.5)

ISSN: 2050-6511